Short description
(English)
|
WHO-FIND Ebola Diagnostic Access Coalition
Projet terminé
The Ebola epidemic currently raging in West Africa is the largest in history, and is still growing rapidly. Halting the epidemic depends entirely on identifying infected people and isolating them to prevent ongoing transmission. There is an urgent need for new rapid, point of contact/care Ebola tests to be used in decentralized health care facilities and not requiring extensive biosafety requirements. Under overall leadership of WHO, an Ebola Diagnostics Access Coalition (EDAC) has been established.
| Pays/région |
Thème |
Période |
Budget |
Afrique
|
Santé
Maladies transmissibles
|
01.12.2014 - 01.07.2016
|
CHF 1'000'000
|
| Contexte |
The current Ebola outbreak poses a serious security problem. On 8 August 2014, the Director-General of the World Health Organization declared the Ebola outbreak a Public Health Emergency of International Concern. Up to the end of 14 October a total of 9,216 cases and 4,555 deaths have been reported in seven affected countries (Guinea, Liberia, Nigeria, Senegal, Sierra Leone, Spain, and the United States of America). Fatality rate is between 25% and 90%, with an average of 50%. In the absence of a vaccine, halting the epidemic depends entirely on identifying infected people and isolating them to prevent ongoing transmission. There is growing recognition that while specialized laboratories are very important, they cannot address all the diagnostic needs of the current Ebola outbreak. There is thus an urgent need for new rapid, point of contact/care Ebola tests to be used in decentralized health care facilities and not requiring extensive biosafety requirements. In reaction to the need of a coordinated effort, under overall leadership of WHO, an Ebola Diagnostics Access Coalition (EDAC), with Working Groups on Development, Evaluation, and Implementation has been established, and a series of key activities to minimize the barriers faced by new technologies identified.
|
| Objectifs |
Through coordinated research and development of new appropriate and accessible Ebola diagnostic tests, contribute to halting Ebola transmission
|
| Groupes cibles |
Ebola affected patients, their contacts and Ebola exposed people worldwide, in particular in the most affected countries Liberia, Sierra Leone and Guinea.
|
| Effets à moyen terme |
- To speed the development of relevant assays by providing access to testing standards and clinical materials.
- To speed assay evaluation with a rapid trialing platform that accounts for logistical, statistical, ethical, regulatory, biosafety, and technical necessities.
- To anticipate and facilitate early and rapid implementation.
- To facilitate communication and coordination between the diverse parties relevant to the development, evaluation, and use of new Ebola diagnostics.
|
| Résultats |
Principaux résultats attendus:
- Collaborative relationship with a suitable biological safety laboratory 4 (BSL4) to carry out the testing.
- Established ethical and reasoned mechanisms to compile a virtual specimen bank that includes enough samples to carry out at least 4 trials.
- Established consensus protocols that provide reasonable evidence of performance, but that are implementable in an abbreviated time frame.
- Coordinated use of existing supply chains and logistics support plans for implementation of new technologies, once approved
- Maintained databases that document the landscape of diagnostic needs (as they evolve) and opportunities (as technical alternatives arise or new companies develop assays).
Principaux résultats antérieurs:
This is a single phase credit proposal without previous phases.
Since 2013 SDC supports the Foundation of Innovative New Diagnostics (FIND) which is proposed to host the Secretariat of the Ebola Diagnostic Access Coalition.
|
| Direction/office fédéral responsable |
DDC
|
| Crédit |
Coopération au développement
|
| Partenaire de projet |
Partenaire contractuel
Organisme des Nations Unies (ONU)
- Organisation mondiale de la santé
Autres partenaires
WHO collaborating centers, UNICEF, the World Bank, Médicins sans Frontières, the US Centers for Disease Control and Prevention (CDC), the US Department of Defense, African Society for Laboratory Medicine (ASLM), and the US National Institute of Health (NIH).
|
| Coordination avec d'autres projets et acteurs |
Foundation for Innovative New Diagnostics (FIND)
|
| Budget |
Phase en coursBudget de la SuisseCHF 1'000'000 Budget suisse déjà attribué CHF 1'000'000 |
| Phases du projet |
Phase 1 01.12.2014 - 01.07.2016 (Completed)
|
|
